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Alterations in serum kynurenine 
pathway metabolites in individuals 
with high neocortical amyloid-β 
load: A pilot study
Pratishtha Chatterjee1,2, Kathryn Goozee  1,2,3,4,5,7, Chai K. Lim1, Ian James8, Kaikai Shen9, 
Kelly R. Jacobs1, Hamid R. Sohrabi1,2,5,6, Tejal Shah1,2,6, Prita R. Asih3,10, Preeti Dave1,4, 
Candice ManYan4, Kevin Taddei2,6, David B. Lovejoy1, Roger Chung1, Gilles J. Guillemin  1 & 
Ralph N. Martins1,2,3,5,6,7
The kynurenine pathway (KP) is dysregulated in neuroinflammatory diseases including Alzheimer’s 
disease (AD), however has not been investigated in preclinical AD characterized by high neocortical 
amyloid-β load (NAL), prior to cognitive impairment. Serum KP metabolites were measured in 
the cognitively normal KARVIAH cohort. Participants, aged 65–90 y, were categorised into NAL+ 
(n = 35) and NAL− (n = 65) using a standard uptake value ratio cut-off = 1.35. Employing linear 
models adjusting for age and APOEε4, higher kynurenine and anthranilic acid (AA) in NAL+ versus 
NAL− participants were observed in females (kynurenine, p = 0.004; AA, p = 0.001) but not males 
(NALxGender, p = 0.001, 0.038, respectively). To evaluate the predictive potential of kynurenine or/and 
AA for NAL+ in females, logistic regressions with NAL+/− as outcome were carried out. After age and 
APOEε4 adjustment, kynurenine and AA were individually and jointly significant predictors (p = 0.007, 
0.005, 0.0004, respectively). Areas under the receiver operating characteristic curves were 0.794 using 
age and APOEε4 as predictors, and 0.844, 0.866 and 0.871 when kynurenine, AA and both were added. 
Findings from the current study exhibit increased KP activation in NAL+ females and highlight the 
predictive potential of KP metabolites, AA and kynurenine, for NAL+. Additionally, the current study 
also provides insight into he influence of gender in AD pathogenesis.
The main physiological roles of tryptophan metabolism are to generate serotonin and melatonin and also, the 
essential co-factor nicotinamide adenine dinucleotide (NAD+) through the kynurenine pathway (KP) (Fig. 1). 
In neuroinflammatory conditions, the KP is strongly up regulated leading to the production of several neuroac-
tive metabolites that can be either neuroprotective, neurotoxic or immuno-modulatory. It has previously been 
demonstrated that the KP is activated in several neurodegenerative and neuropsychiatric disorders including 
Alzheimer’s disease (AD)1–6.
Interestingly, this central dysregulation of the KP homeostasis also manifests in the blood in AD patients7–9. 
Higher ratios of KP metabolites, kynurenine (KYN) to tryptophan (K:T) in serum and plasma have been reported 
in patients with AD and mild cognitive impairment (MCI)10,11 and this ratio (K:T) also inversely correlated with 
cognitive performance10. Further, a decline in plasma and erythrocyte concentrations of the KP metabolite 
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kynurenic acid (KYNA), which is produced via a secondary branch of the KP and precludes NAD+ production 
from KYN, has been reported in patients with AD and MCI11,12. Furthermore, elevated plasma levels of the exci-
totoxin quinolinic acid, have been reported in AD7. Additionally, a relatively recent study reported an association 
between dementia risk and elevated plasma levels of the KP metabolite, anthranilic acid (AA)13.
However, KP metabolite alterations have never been investigated in the preclinical stage of AD that is char-
acterised by high neocortical amyloid-β load (NAL)14 measured via positron emission tomography (PET), prior 
to cognitive decline, given that the deposition of NAL begins to occur two to three decades prior to the clinical 
manifestation of the disease15.
Therefore, the current pilot study investigated whether the dysregulation of the KP occurs within the preclin-
ical stage of the AD pathogenesis trajectory, in cognitively normal individuals. Serum tryptophan and KP metab-
olites, primarily comprising, KYN, KYNA, 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), 
AA, picolinic acid and quinolinic acid, were hence measured in, and compared between, cognitively normal 
individuals with preclinical AD characterised by high NAL (NAL+; standard uptake value ratio (SUVR) ≥1.35) 
and individuals with no apparent risk to AD, characterised by low NAL (NAL−, SUVR <1.35)16–18.
Results
Comparison of demographic characteristics between NAL− and NAL+ participants. 
Demographic characteristics of study participants have been presented in Table 1 (and demographic characteris-
tics stratified by gender are available in Supplementary Table 1). As expected, the APOE ε4 carriage frequency was 
significantly higher in NAL+ participants (45.7%) compared to NAL− participants (7.7%)18–20. No significant 
differences were observed in age, gender, body mass index, MMSE scores, MoCA scores, years of education, sex 
hormone levels and hippocampal volume between NAL− and NAL+ cohort participants (Table 1).
KP metabolites and the three major AD risk factors i.e. age, APOE ε4 carriage and gender. 
When the association between KP metabolites and AD risk factors were investigated, among the KP metabolites, 
quinolinic acid positively correlated with age (p < 0.05, Supplementary Table 2), while no significant differences 
in KP metabolites were observed with respect to APOE ε4 carriage (Supplementary Table 3). However, signifi-
cantly higher concentrations of KP metabolites, KYNA and 3-HAA, were observed in males compared to females, 
uncorrected and corrected for covariates age and APOE ε4 status (p ≤ 0.005, Supplementary Table 4).
Figure 1. Schematic diagram of the kynurenine pathway. Tryptophan can be utilised for protein synthesis 
or serotonin and melatonin production. However, over 90% peripheral tryptophan has been reported to be 
metabolised via the kynurenine pathway (KP) in mammals. In the KP, tryptophan is metabolised into N-formyl-
kynurenine followed by kynurenine (KYN) catalysed by enzymes indoleamine deoxygenase or tryptophan 
deoxygenase and formamidase. KYN is then converted to kynurenic acid (KYNA) by enzyme kynurenine 
aminotransferase. Alternatively, KYN is metabolised to anthranilic acid (AA) and 3-hydroxykynurenine (3-
HK) by enzymes kynureninase and kynurenine-3-monooxygenase, respectively. AA and 3-HK further get 
metabolised to 3-hydroxyanthranilic acid (3-HAA), which in turn gets converted to aminocarboxymuconic 
semialdehyde (ACMA). ACMA spontaneously converts to neurotoxin, quinolinic acid, a substrate for the redox 
agent, NAD+. Alternatively, ACMA can be assisted by enzyme 2-amino-3-carboxymuconatesemialdehyde 
decarboxylase to generate picolinic acid. KP metabolites marked in bold, have been investigated in the current 
study.
www.nature.com/scientificreports/
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KP metabolites and NAL. Serum kynurenine and anthranilic acid levels were significantly elevated in 
NAL+ versus NAL− participants uncorrected and corrected for age, gender, APOE ε4 status and education 
(Supplementary Table 5). However, on comparing KP metabolites between NAL− and NAL+ cohort partici-
pants, after adjustment for age, gender and APOE ε4 status, there were significant differences between the associ-
ations of metabolites and NAL+/− according to gender for KYN (p = 0.001), 3- HK (p = 0.001), AA (p = 0.038) 
and QA (p = 0.007). In particular, KYN was significantly higher for NAL+ vs NAL− in females (p = 0.004), but 
not significantly different in males; 3-HK was higher for NAL+ vs NAL− in females (p = 0.017) but lower in 
males (p = 0.022); and AA was higher for NAL+ vs NAL− in females (p = 0.001) but not for males. QA showed 
a tendency to increase for NAL+ vs NAL− in females and to decrease in males, but neither were individually 
significant (Fig. 2, Supplementary Table 6, demographics available in Supplementary Table 1). Additionally, given 
the complex interaction between KP metabolites and that the generation of KYNA precludes the formation of AA 
given their common precursor (KYN, see Fig. 1), we also investigated K:T and AA:KYNA ratios, wherein both 
were observed to be significantly higher in NAL+ versus NAL− female participants (Supplementary Table 6).
While no correlation between NAL (as a continuous variable) and KP metabolites were observed in male par-
ticipants, NAL significantly correlated with KYN and AA without adjusting for covariates (Fig. 3) and KYN, AA, 
3-HK and 3-HAA after correcting for covariates age and APOE ε4 status in female participants (Supplementary 
Table 7). The observation of 3-HAA significantly correlating with NAL in the females, but not being signifi-
cantly elevated in NAL+ versus NAL− for this gender (Supplementary Table 6) can be attributed to the fact 
that 3-HAA correlated with NAL (correcting for age and APOE ε4 status) only within the NAL+ female subset 
(n = 22, ra = 0.572, pa = 0.008).
Potential of KP metabolites to predict NAL+. Given that significantly elevated KYN and AA con-
centrations, in particular, were observed in NAL+ (versus NAL−) female sera we evaluated these and other 
metabolites as potential markers in females to predict NAL+ via logistic regression with NAL+/− as response. 
After adjusting for age and APOE ε4 status, all metabolites were entered jointly (on the log scale) and backward 
elimination was used to obtain the simplest model containing only significant terms. Only KYN (p = 0.03) and 
AA (p = 0.045) remained jointly significant (joint p = 0.0004). A ‘base’ model incorporating the major risk fac-
tors for AD, age and APOE ε4 allele status, was then generated and compared to the ‘base+ KYN’, ‘base+ AA’ 
and ‘base+ KYN+ AA’ models, wherein either KYN, AA or both KYN and AA concentrations were added to 
the base model (Fig. 4). The area under the curve (AUC) of the ‘base+ KYN’ (AUC = 0.843, specificity = 52% at 
sensitivity = 90%, log(KYN) p = 0.007), ‘base+ AA’ (AUC = 0.865, specificity = 83% at sensitivity = 90%, log(AA) 
p = 0.005) and ‘base+ KYN+ AA’ model (AUC = 0.87, specificity = 65% at sensitivity = 90%) outperformed the 
‘base’ model (AUC = 0.794, specificity = 43% at sensitivity = 90%) in distinguishing NAL+ from NAL− par-
ticipants. While it is marginally significant on its own as an additional predictor for NAL+, the K:T ratio is not 
significant when AA is already included (p = 0.47).
Discussion
In mammals, the KP has been reported to account for over 90% of peripheral tryptophan catabolism21. Our 
findings exhibit aberrant peripheral tryptophan metabolism, via the KP, in preclinical AD wherein, significantly 
elevated KYN, AA and 3-HK serum concentrations were present in NAL+ versus NAL− females. Additionally, 
NAL− NAL+ p
Gender (M/F) 19/46 13/22 0.419
Age (years, mean ± SD) 77.61 ± 5.55 79.22 ± 5.38 0.165
BMI (mean ± SD) 27.38 ± 4.47 28.05 ± 4.73 0.486
nAPOE ε4 carriers (%) 5 (7.7) 16 (45.7) <0.0001
MMSE (mean ± SD) 28.50 ± 1.16 28.80 ± 1.10 0.225
MoCA (mean ± SD) 27.43 ± 1.67 27.03 ± 1.92 0.278
Education (years, mean ± SD) 14.84 ± 3.37 13.64 ± 2.91 0.078
Testosterone (nmol/L, mean ± SD), males 14.43 ± 6.16 11.66 ± 3.77 0.160
Testosterone (nmol/L, mean ± SD), females 1.45 ± 2.55 1.26 ± 0.81 0.738
Oestradiol (pmol/L, mean ± SD), males 113.16 ± 47.83 117.23 ± 35.17 0.795
Oestradiol (pmol/L, mean ± SD), females 91.22 ± 118.71 73.90 ± 28.97 0.523
FBB-PET SUVR (mean ± SD, n = 100) 1.15 ± 0.08 1.71 ± 0.26 —
HV% (left; right lobes, mean ± SD, n = 96) 0.195 ± 0.020; 0.199 ± 0.021
0.194 ± 0.019; 
0.199 ± 0.018 0.805; 0.890
Table 1. Demographic characteristics of cohort participants. Baseline characteristics including gender, age, 
body mass index (BMI), APOE ε4 status, mini mental state examination (MMSE) scores, Montreal Cognitive 
Assessment (MoCA, adjusted for education) scores, years of education, sex hormone levels, neocortical amyloid 
load (NAL) represented by the standard uptake value ratio (SUVR) of ligand 18F-Florbetaben (FBB) in the 
neocortical region normalised with that in the cerebellum, and hippocampal volume (HV) normalised by the 
intracranial volume, have been compared between NAL− (SUVR <1.35) and NAL+ (SUVR ≥1.35) study 
participants. Chi-square test or linear models were employed as appropriate. Ninety-six participants underwent 
MRI (nNAL− = 64, nNAL+ = 32).
www.nature.com/scientificreports/
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within female study participants, a significant positive correlation was observed between NAL and the aforemen-
tioned serum KP metabolite concentrations.
Similar to findings in the current preclinical AD study, elevated serum KYN concentrations and K:T ratios 
have been reported previously in clinical AD and in individuals with MCI10,11. The foremost step in the KP i.e. the 
generation of KYN from tryptophan, via N-formyl-KYN, is catalysed by enzymes indoleamine 2,3-dioxygenase 
1(IDO1; predominantly expressed in extra-hepatic cells such as neurons, macrophages, microglia and astrocytes) 
or tryptophan 2,3-dioxygenase (TDO; predominantly expressed in hepatocytes)22–25. Significantly higher IDO1 
and TDO immunoreactivity has been reported in AD patient hippocampi3,26. Further, IDO1 and TDO, have been 
reported to be regulated by immune system signalling molecules, growth factors and steroids1,22,27,28, all of which 
Figure 2. Comparison of kynurenine pathway metabolites between NAL− and NAL+ participants, separately 
in males and females. Kynurenine pathway metabolite concentrations in serum were compared between 
participants (in A. Males and B. Females, separately) with neocortical amyloid-β load (NAL, assessed by 
the standard uptake value ratio observed via positron emission tomography using ligand 18F-florbetaben) 
<1.35 (NAL−) and ≥1.35 (NAL+) using linear models. Kynurenine (KYN), anthranilic acid (AA) and 
3-hydroxykynurenine (3-HK) levels were significantly higher in NAL+ (N = 22) compared with NAL− 
(N = 46) female participants while 3-hydroxykynurenine (3-HK) levels were significantly lower in NAL+ 
(N = 13) compared with NAL− (N = 19) male participants. The line segment within each box plot represents 
the median within each box plot and error bars represent the range of the metabolite concentration for each 
group. *Represents p < 0.05, **represents p ≤ 0.01 and ***represents p < 0.0005; p values were obtained from 
variables transformed to the logarithmic scale for analyses to meet assumptions of the statistical test employed. 
TRP, tryptophan; KYNA, kynurenic acid; HAA, 3-hydroxyanthranilic acid; PA, picolinic acid; QA, quinolinic 
acid. (A) Serum metabolite concentrations in males. (B) Serum metabolite concentrations in females.
www.nature.com/scientificreports/
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have been shown to be associated with AD pathogenesis29–33. Our findings of elevated serum KYN concentrations 
along with higher K:T ratios in NAL+ versus NAL− participants together with the afore cited literature are there-
fore indicative of increased tryptophan degradation via the KP, from the preclinical stages of the AD pathogenesis 
trajectory, prior to cognitive impairment.
Given the observation of significantly increased KP activation in NAL+ participants, apparent from the ele-
vated serum KYN concentrations and K:T ratios in NAL+ (female) participants within the current study, further 
investigation of downstream KP metabolites revealed elevated AA serum concentrations in females. This obser-
vation is further corroborated by a study conducted by Chouraki and colleagues that reported elevated serum AA 
concentrations in cognitively normal individuals who later developed dementia13. However, AA concentrations 
were not reported to be significantly elevated in a study examining KP metabolites in clinical AD7. Taken together 
with the findings of Chouraki and colleagues, we specifically demonstrate elevated AA levels as a feature of NAL+ 
preclinical AD that is predictive of converting to clinical AD. However, our study shows a strong gender effect, 
namely in females.
Additionally, it is important to note that even though both precursors to 3-HAA (AA, 3-HK) are elevated in 
NAL+ females, 3-HAA itself is not elevated in NAL+ females. Interestingly, Chouraki and colleagues reported a 
trend of association between plasma 3-HK and decreased risk of incident dementia, even though plasma anthra-
nilic acid levels were observed to be associated with increased risk of incident dementia13. One possible explana-
tion could be that the enzyme (activity) that catalyses the production of 3-HAA is decreased in NAL+, however, 
further studies are required to investigate this notion.
While the influence of gender on serum KP metabolite concentrations has been reported previously34, to our 
knowledge, no previous study has reported significantly elevated KYN (or K:T ratio) or/and AA or/and 3-HK 
restricted to the female population, in AD pathogenesis, as observed within the current study. It is however 
acknowledged that the current cohort may have lacked sufficient power within the male subset given its mod-
est sample size (19 NAL− males/13 NAL+ males). Three-HK was observed to significantly increase in NAL+ 
females compared to NAL− females but decrease in NAL+ males compared to NAL− males. While the mecha-
nism behind these observations are currently not known, our results further exhibit the strong gender difference 
in AD pathogenesis (Supplementary Table 6). Schwarz and colleagues reported elevated 3-HK serum concentra-
tions in AD, which support our findings in preclinical female participants. Interestingly, the clinical AD group in 
the study by Schwarz and colleagues comprised 80% females (16 females/4 males)8. Given the paucity of literature 
describing the impact of gender on the relationship between AD pathology and 3-HK and particularly the rela-
tively small sample size of males in both studies, further investigations are warranted on KP metabolite alterations 
in AD pathogenesis, in larger male and female cohorts.
Further, the current study observed a strong interaction effect between NAL and gender on KP metabolites 
that may be attributed to the influence of sex hormones on the enzymes involved within the KP35. For example, 
testosterone has been reported to have an inhibitory effect on the KP (via TDO/IDO1 by reducing NAD produc-
tion in favour of KYNA formation)36,37 while oestrogen has been reported to induce (via TDO/IDO1 favouring 
NAD+ production, precluding KYNA formation)38 as well as inhibit the KP (by inhibiting immune system activa-
tion)39. However, the incidence of ageing-related hormonal changes prevalent within the KARVIAH cohort and 
the complex interplay and feedback mechanisms between the various KP metabolites also need to be considered 
with regard to observations in this study. Within the current study, it may be posited that elderly women were 
more vulnerable (NAL+ vs NAL−) to increased KP activity compared to elderly men, given the postmenopausal 
plummet in oestrogen which increases vulnerability to AD, while in similarly aged men40, testosterone levels are 
relatively stable which may confer neuroprotection32,33,41–45.
In addition to the influence of the sex hormones, other mechanisms resulting in increased KP activation 
contributing to AD pathogenesis may also be involved. Given that inflammation is an early feature in the AD 
pathogenesis trajectory, inflammation induced immune responses occurring in AD pathogenesis, may upreg-
ulate IDO activity and tryptophan degradation resulting in increased KP activation46,47. Although the current 
study addresses the peripheral concentrations of KP metabolites, blood concentrations of tryptophan, KYN, AA 
Figure 3. Correlation between NAL and KP metabolites, KYN and AA, in females. Significant correlations 
were observed between neocortical amyloid-β load (NAL) and serum concentrations of (A) kynurenine (KYN; 
r = 0.346, p = 0.004, n = 68) (B) anthranilic acid (AA; r = 0.449, p = 0.0001, n = 68) using Pearson’s correlation 
coefficient (r), in females. Correlation coefficients after adjusting for covariates age and APOEε4 are available 
in Supplementary Table 6. Serum KYN and AA concentrations were transformed to the logarithmic scale for 
analyses, to meet assumptions of the statistical test employed.
www.nature.com/scientificreports/
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and 3-HK significantly contribute to the brain pools of these metabolites (~60%), given their permeability to the 
blood brain barrier48,49. Therefore, elevated KYN, AA and 3-HK in NAL+ serum may consequently enhance 
KYN, AA and 3-HK concentrations in NAL+ brains. Given that the two branches of the KP occur in a segre-
gated manner in the brain, wherein 3-HK and its further downstream metabolites occur in the microglia (while 
KYNA is formed in the astrocytes)25, we posit that an increase in KP intermediate substrates impact microglial 
activation inducing secretion of inflammatory signalling molecules. This inflammation could further induce Aβ 
generation, in turn triggering further inflammation, resulting in a vicious cycle50. Aβ has been reported to induce 
interferon-γ51, a potent activator of IDO52, resulting in increased KP activity53, further leading to elevated con-
centrations of KYN and its downstream metabolites, such as AA. It could be argued that elevations in AA concen-
trations in NAL+ versus NAL− may actually represent a protective mechanism against AD pathogenesis due to 
the presence of iron dyshomeostasis in preclinical AD17,54, given that AA is known to have reactive oxygen species 
scavenging properties by iron chelation55.
The current pre-mortem gold standard biomarkers for preclinical AD, namely NAL measured via PET 
(employed within the current study) and cerebrospinal fluid (CSF) concentrations of Aβ42 and tau, are uneco-
nomical and invasive, respectively. Therefore, we also evaluated the KP metabolite alterations observed within 
the present study as potential blood biomarkers for preclinical AD or NAL+ . We found significant KP metabolite 
alterations that reflect NAL positivity in females. Interestingly, the addition of AA to a base model comprising age 
and APOE ε4 allele status, resulted in an increased specificity from 43% to 83%, at a sensitivity of 90%, indicating 
that AA may serve as a statistically significant predictor of NAL over and above the base model, in elderly females.
We acknowledge that the current study has limitations such as the cross-sectional nature of the study and the 
relatively modest sample size of the cohort whereby the male subset may have lacked sufficient power, contribut-
ing to the absence of significant KP metabolite alterations observed in the female cohort subset. However, given 
that sex hormones play an important role in regulating the KP, it is highly likely that the findings in our study 
will be replicated in a larger cohort. Additionally, given the modest sample size and pilot nature of the study, 
we have not corrected for multiple testing. However, our findings of significantly elevated KYN and AA levels 
in NAL+ females compared to NAL− females remain significant following Bonferroni correction for multiple 
testing (KYN, p = 0.03; AA, p = 0.01). Furthermore, although KYN and AA significantly add to the predictive 
potential of the base model comprising the three major risk factors of AD (namely age, APOE ε4 and gender) for 
NAL+, further confirmatory studies are required.
Finally, to conclude, the current study reports KP metabolite alterations in preclinical AD (characterised 
by high NAL) females wherein, serum concentrations of KYN, AA and 3-HK were elevated prior to cogni-
tive impairment and hippocampal atrophy. To our knowledge, this is also the first study to report an associa-
tion between concentrations of the aforementioned metabolites with NAL, a gold standard biomarker of AD. 
Importantly, the current study also identifies potential blood biomarkers for preclinical AD. Interestingly, our 
findings were restricted to the female subset of the cohort, which may provide further insight into the gender 
effects in AD pathogenesis. While our observations could be attributed to the several mechanisms hypothesised 
above, further validation studies are warranted. Given the preliminary nature of the current findings, confirma-
tion in a larger sample set is required. Additionally, future studies are also required to measure the KP enzyme 
activities, in addition to employing male predominant cohorts and longitudinal studies, to gain further insight 
into these current findings.
Methods and Materials
Participants. Study participants were from the Kerr Anglican Retirement Village Initiative in Ageing Health 
(KARVIAH) cohort, at baseline. All participants were residents of Anglicare, New South Wales, Australia.
Cohort volunteers (N = 206) were screened for the inclusion and exclusion criteria of the KARVIAH cohort17. 
The inclusion criteria for the KARVIAH Study briefly comprised, an age range of 65–90 years, good general 
health, no known significant cerebral vascular disease, fluent in English, adequate/corrected vision and hear-
ing to enable testing, no objective cognitive impairment measured using a Montreal Cognitive Assessment 
(MoCA) cut-off score ≥2656. MoCA scores lying between 18–25 were assessed on a case by case basis by the 
study neuropsychologist following stratification of scores according to age and education norms57. The exclusion 
Figure 4. Receiver operating characteristic (ROC) curves for the prediction of high neocortical amyloid-β 
load in female participants. The ‘base’ model comprising major risk factors age and APOE ε4 allele status (A) 
was outperformed by the ‘base+ kynurenine’ model (B) and the ‘base+ anthranilic acid’ model (C) and ‘base+ 
kynurenine+ anthranilic acid’ model (D). Logistic regression models were employed to perform the analyses. 
AUC: area under the curve.
www.nature.com/scientificreports/
7SCIENTIFIC RePoRtS |  (2018) 8:8008  | DOI:10.1038/s41598-018-25968-7
criteria comprised, the diagnosis of dementia based on the revised criteria from the National Institute on Aging - 
Alzheimer’s Association58, presence of acute functional psychiatric disorder (including lifetime history of schiz-
ophrenia or bipolar disorder), history of stroke, severe or extremely severe depression (based on the depression, 
anxiety, stress scales; DASS) and uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100).
One hundred and five participants out of the 134 volunteers meeting the inclusion/exclusion criteria, under-
went neuroimaging, neuropsychometric evaluation and blood collection, as the remaining either declined neu-
roimaging or withdrew from the study. Within these 105 participants, 100 participants were considered to be 
cognitively normal based on their Mini-Mental State Examination score59 (MMSE ≥26), and were included in 
the current study. Concentrations of the KP metabolites in the serum were reported in all 100 participants with 
MMSE ≥26. All experimental protocols were approved by the Bellberry Human Research Ethics Committee, 
Australia and were performed in accordance with the relevant guidelines and regulations. The study volunteers 
provided written informed consent prior to participation, and the Bellberry Human Research Ethics Committee, 
Australia, provided ethical approval for the study.
Evaluation of neocortical amyloid-β load and hippocampal volumes via PET and MRI. Study 
participants were imaged within three months of blood collection. Participants underwent positron emission 
tomography (PET) using ligand 18F-Florbetaben (FBB), and magnetic resonance imaging (MRI) at Macquarie 
Medical Imaging in Sydney.
All 100 participants within the current study underwent FBB-PET. Participants were administered an intrave-
nous bolus of FBB slowly over 30 s, while in a rested position. Images were acquired over a 20 min scan, in 5 min 
acquisitions, beginning 50 min post injection. Neocortical amyloid load was calculated as the mean SUVR of the 
ligand FBB in the frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate 
regions normalised with that in the cerebellum using image processing software, CapAIBL60,61.
Ninety-six of the 100 participants within the current study passed all standard MRI inclusion/exclusion crite-
ria, and underwent MRI as described previously using a General Electric (GE) 3Tesla scanner (Model 750 W)16. 
Hippocampal volume calculated from the images acquired was normalized with the total intracranial volume 
comprising the cerebrospinal fluid, grey matter and white matter.
Blood collection and processing, and measurement of KP metabolites in serum. All study par-
ticipants fasted for a minimum of 10 hours overnight prior to blood collection employing standard serological 
methods and processing techniques for serum collection as described previously17,20. Serum samples were col-
lected in the year 2015 and stored at −80 °C until thawed for measurement of KP metabolites in the year 2017.
All reagents and KP metabolite standards were analytical reagent grade and were purchased from 
Sigma-Aldrich (St Louis, MO), unless otherwise stated. Deuterated internal standards were purchased from 
Medical Isotopes, Inc (Pelham, NH). Serum samples were prepared for KP metabolite analyses with the addition 
of equal volumes of 10% (w/v) trichloroacetic acid (TCA).
Analyses of tryptophan, KYN, 3-HK, 3-HAA and AA were performed simultaneously with ultra high perfor-
mance liquid chromatography (UHPLC) with an injection volume of 20 μL per sample, as described previously46. 
KYNA separation was carried out following injection (10 µL) onto a Poroshell RRHT C-18, 1.8μm 2.1 × 100 mm col-
umn (Agilent Technologies, Inc, Santa Clara, CA) and quantified via fluorescence detection (excitation and emission 
wavelengths of 344 nm and 388 nm, respectively; retention time 1.5 min). A gradient method with 50 mM sodium 
acetate, 25 mM zinc acetate and 2.25% acetonitrile (Eluent A), and 10% acetonitrile (Eluent B) was employed and 
separation was performed at 38 °C with a flow rate of 0.75 mL/min. Separation achieved over 10 min, comprised 
100% eluent A for 3 min, 50% eluent A for 2 min, 0% eluent A for 2 min and re-equilibration with 100% eluent A for 
3 min. Data were analysed with the Agilent OpenLAB CDS ChemStation (Edition C.01.04).
For gas chromatography coupled with mass spectrometry (GCMS), 50 μL of sample extract was derivatized. 
Simultaneous analysis of picolinic acid and quinolinic acid were performed as described previously62 with minor 
modifications using an Agilent 7890 A GC system coupled with Agilent 5975 C mass spectrometry detector and 
Agilent 7693 A autosampler (Agilent Technologies, Inc, Santa Clara, CA) with one microliter of derivatized mix-
ture. Separation of picolinic acid and quinolinic acid were achieved with a DB-5MS column, 0.25μm film thick-
ness, 0.25 mm × 30 m capillary column (Agilent Technologies, Inc, Santa Clara, CA) within 7 min but the assay 
run time was set for 12 min to prevent sample carryover. Picolinic acid and quinolinic acid concentrations were 
analysed using Agilent GC/MSD ChemStation software (Edition 02.02.1431) and interpolated from the estab-
lished six-point calibration curves based on the abundance count ratio of the metabolites to their corresponding 
deuterated internal standards within each standard and sample. The intra- and inter-assay CV was within the 
acceptable range (4–8% for UHPLC assays, 7–10% for GCMS assays) calculated from the repeated measures of 
the metabolite standards incorporated during the sequence run.
APOE genotyping. Apolipoprotein E (APOE) genotype was determined from purified genomic DNA 
extracted from 0.5 ml whole blood, wherein each sample was genotyped for the presence of the ε2, ε3, and ε4 
APOE variants based on TaqMan SNP genotyping assays for rs7412 (C 904973) and rs429358 (C 3084793) as per 
the manufacturer’s instructions (AB Applied Biosystems by Life Technologies, Victoria, Australia).
Statistical analyses. Descriptive statistics including means and standard deviations or proportions were 
calculated for NAL+ and NAL− groups, with comparisons employing t-tests or Chi-square tests as appropriate 
in Table 1. Linear models were employed to compare continuous variables (KP metabolites) between categories 
corrected for covariates age, gender, APOE ε4 carrier status and years of education. Response variables were 
log transformed as necessary to better approximate normality and variance homogeneity. Differences in asso-
ciation of the KP metabolites with NAL+/− for females and males were assessed by incorporation of gender 
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by NAL interactions into the models. Pearson correlations (r) and partial correlations (ra, adjusting for age and 
APOE ε4 carrier status and rb, adjusting for age, APOE ε4 carrier status and education) were employed to eval-
uate the strength of the association between KP metabolites and neocortical Aβ deposition. Logistic regression 
with NAL−/+ as response was used to evaluate predictive models and receiver operating characteristic curves 
constructed from the logistic scores. All analyses were carried out using IBM® SPSS® Version 23 and receiver 
operating characteristic (ROC) curves were generated using the package Deducer on R (version 3.2.5). The data-
sets generated and analysed during the current study are available from the corresponding author on reasonable 
request.
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